Protalix BioTherapeutics Inc. - PLX Projected Sales Volume

The Protalix BioTherapeutics biotech pipeline is steadily evolving through the modernization of protein synthesis processes. The innovative ProCellEx platform minimizes contamination risks, creating a pricing barrier for competitors. Prospects depend on clinical trials and partner payments. The company's future sales metric on the GURU.Markets chart demonstrates market potential, where 0.03 shows the current volume of the indicator.

PLX - Protalix BioTherapeutics Projected Sales Volume over the range 07/04/2022 - 11/13/2026

Metric breakdowns and analytics for Protalix BioTherapeutics Inc. (PLX)

- stock value and consensus price forecast:

Price Chart Protalix BioTherapeutics|PLX - Forecast Levels Chart

- issuer market value details:

Market Capitalization Protalix BioTherapeutics Inc.|PLX - Value Adjusted for Debt and Cash

- book capitalization information:

Book Value per Share Protalix BioTherapeutics|PLX - Book Capitalization|Market Value to Book Value Ratio protalix.com|PLX - Aggregate Asset Value

- debt burden and liquidity indicators:

- earnings and market ratios statistics:

PLX - Company Net Income|Future Profit Protalix BioTherapeutics|PLX - Market Price to Net Income Ratio|Forward P/E Multiple Protalix BioTherapeutics, Inc.|PLX - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protalix BioTherapeutics Inc.|PLX - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Protalix BioTherapeutics|PLX - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months protalix.com|PLX - Earnings per share growth this year|Expected earnings per share growth for next year Protalix BioTherapeutics

- sales volume and revenue indicators:

PLX - Company Sales Revenue|Projected Sales Volume Protalix BioTherapeutics|PLX - Price-to-Revenue Ratio|Forward P/S Multiple Protalix BioTherapeutics Inc.

Comprehensive company analysis:PLX Protalix BioTherapeutics

Signature product of Protalix BioTherapeutics Inc.

This indicator measures projected revenue, reflecting market expectations for capital inflows and real demand for the issuer's assets within the fundamental valuation. By analyzing the future sales volume chart, an investor can assess the resilience of Protalix BioTherapeutics (PLX), whose business model maintains stability due to the humanitarian status of its drugs, even amidst regional tensions in the Middle East.

Competitor analysis for Protalix BioTherapeutics